Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by VBI Vaccines Inc.
< Previous
1
2
3
Next >
VBI Vaccines Reports Full Year 2022 Financial Results
March 13, 2023
From
VBI Vaccines Inc.
Via
Business Wire
Tickers
VBIV
VBI Vaccines to Discuss Progress in Hepatitis B Portfolio in Analyst-Led Fireside Chat
February 23, 2023
From
VBI Vaccines Inc.
Via
Business Wire
Tickers
VBIV
VBI Vaccines Announces Presentation of Interim Phase 2 Data Evaluating Combination of VBI-2601 (BRII-179) and BRII-835 for the Treatment of Chronic Hepatitis B
February 15, 2023
From
VBI Vaccines Inc.
Via
Business Wire
Tickers
VBIV
VBI Vaccines Announces Health Canada Approval for PreHevbrio™ for the Prevention of Hepatitis B in Adults
December 08, 2022
From
VBI Vaccines Inc.
Via
Business Wire
Tickers
VBIV
CEPI Boosts ‘Coronavirus X’ Vaccine Search With Expanded VBI Vaccines Deal
December 06, 2022
From
VBI Vaccines Inc.
Via
Business Wire
Tickers
VBIV
VBI Vaccines Presents Additional Phase 1/2a Data from VBI-1901 in Recurrent GBM at the 2022 Society for Neuro-Oncology (SNO) Annual Meeting
November 22, 2022
From
VBI Vaccines Inc.
Via
Business Wire
Tickers
VBIV
VBI Vaccines to Participate in Upcoming Investor Conferences
November 14, 2022
From
VBI Vaccines Inc.
Via
Business Wire
Tickers
VBIV
VBI Vaccines Announces Presentation of Data from Ongoing Phase 2a Study of VBI-1901 at the 2022 Society for Neuro-Oncology (SNO) Annual Meeting
November 11, 2022
From
VBI Vaccines Inc.
Via
Business Wire
Tickers
VBIV
VBI Vaccines Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 10, 2022
From
VBI Vaccines Inc.
Via
Business Wire
Tickers
VBIV
VBI Vaccines to Participate in H.C. Wainwright 3rd Annual Hepatitis B Virus (HBV) Conference
October 17, 2022
From
VBI Vaccines Inc.
Via
Business Wire
Tickers
VBIV
VBI Vaccines and Agenus Announce Collaboration to Evaluate VBI-1901 in Combination with Anti-PD-1 Balstilimab in a Phase 2 Study in Primary Glioblastoma Patients
October 12, 2022
From
VBI Vaccines Inc.
Via
Business Wire
Tickers
VBIV
VBI Vaccines Announces Initiation of Phase 1 Study of Multivalent Coronavirus Vaccine Candidate, VBI-2901
September 29, 2022
From
VBI Vaccines Inc.
Via
Business Wire
Tickers
VBIV
VBI Vaccines Announces Presentation of Physician-Initiated Compassionate Use Data of its 3-Antigen Hepatitis B Vaccine at the 2022 International HBV Meeting
September 21, 2022
From
VBI Vaccines Inc.
Via
Business Wire
Tickers
VBIV
VBI Vaccines Secures $100 Million Debt Facility From K2 HealthVentures
September 15, 2022
From
VBI Vaccines Inc.
Via
Business Wire
Tickers
VBIV
Valneva and VBI Vaccines Announce European Partnership for Marketing and Distribution of PreHevbri®
September 08, 2022
From
VBI Vaccines Inc.
Via
Business Wire
Tickers
VALN
VBIV
VBI Vaccines Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 08, 2022
From
VBI Vaccines Inc.
Via
Business Wire
Tickers
VBIV
VBI Vaccines Announces Appointment of John Dillman as Chief Commercial Officer
July 12, 2022
From
VBI Vaccines Inc.
Via
Business Wire
Tickers
VBIV
VBI Vaccines Announces New Long-Term Follow-Up Clinical Data for its 3-Antigen Adult Hepatitis B Vaccine Presented at EASL 2022
June 28, 2022
From
VBI Vaccines Inc.
Via
Business Wire
Tickers
VBIV
VBI Vaccines Announces Results of Annual General Meeting
June 22, 2022
From
VBI Vaccines Inc.
Via
Business Wire
Tickers
VBIV
VBI Vaccines Receives U.S. FDA Orphan Drug Designation for VBI-1901 for the Treatment of Glioblastoma
June 22, 2022
From
VBI Vaccines Inc.
Via
Business Wire
Tickers
VBIV
VBI Vaccines to Participate in the Jefferies Healthcare Conference
June 07, 2022
From
VBI Vaccines Inc.
Via
Business Wire
Tickers
VBIV
VBI Vaccines Presents Updated Phase 2a Tumor Response and Overall Survival Data for VBI-1901 in Recurrent GBM at the 2022 ASCO Annual Meeting
June 06, 2022
From
VBI Vaccines Inc.
Via
Business Wire
Tickers
VBIV
VBI Vaccines Announces UK MHRA Marketing Authorisation for PreHevbri™, a 3-Antigen Adult Hepatitis B Vaccine
June 01, 2022
From
VBI Vaccines Inc.
Via
Business Wire
Tickers
VBIV
VBI Vaccines Announces Abstract Accepted for Oral Presentation at EASL 2022
May 26, 2022
From
VBI Vaccines Inc.
Via
Business Wire
Tickers
VBIV
VBI Vaccines Presented Health Economics and Outcomes Research for PreHevbrio™ at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2022
May 19, 2022
From
VBI Vaccines Inc.
Via
Business Wire
Tickers
VBIV
VBI Vaccines Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 09, 2022
From
VBI Vaccines Inc.
Via
Business Wire
Tickers
VBIV
VBI Vaccines Announces European Commission Marketing Authorisation for PreHevbri™, a 3-Antigen Adult Hepatitis B Vaccine
May 02, 2022
From
VBI Vaccines Inc.
Via
Business Wire
Tickers
VBIV
VBI Vaccines Announces Data from VBI-1901 in Recurrent Glioblastoma Patients Selected for Poster Discussion at the 2022 ASCO Annual Meeting
April 28, 2022
From
VBI Vaccines Inc.
Via
Business Wire
Tickers
VBIV
VBI Vaccines Announces New Data and Progress of VBI-2900, VBI’s eVLP Coronavirus Program
April 05, 2022
From
VBI Vaccines Inc.
Via
Business Wire
Tickers
VBIV
VBI Vaccines Announces PreHevbrio™ is Now Available in the United States for the Prevention of Hepatitis B in Adults
March 29, 2022
From
VBI Vaccines Inc.
Via
Business Wire
Tickers
VBIV
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.